Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma - PubMed
2 hours ago
- #bispecific antibodies
- #CAR-T therapy
- #multiple myeloma
- Sequential use of CAR-T cell therapy and bispecific antibodies (BsAb) yields the most favorable survival outcomes in relapsed/refractory multiple myeloma.
- Initiating treatment with CAR-T therapy (like ide-cel, cilta-cel, or cesni-cel) is associated with longer remission periods compared to starting with BsAb.
- Mortality from early disease progression is similar regardless of initial treatment modality, indicating that resistance can negate initial efficacy differences.
- Among CAR-T products, cilta-cel and cesni-cel drive the observed benefits, while BsAb show outcomes comparable or superior to ide-cel.
- Treatment sequencing is critical for optimizing long-term outcomes, emphasizing the need for equitable and timely access to both modalities across healthcare systems.